Sullivan A Nichole, Bryant Elizabeth A, Mark Lawrence A
University of Notre Dame, Indiana, USA.
Cutis. 2012 Mar;89(3):133-6.
The clinical course and outcome of malignant melanoma (MM) are well-established for immunocompetent groups; however, they are not well-documented for immunosuppressed populations. Specifically, the influence of immunosuppression may result in poorer outcomes, especially in more advanced cases of melanoma. We report a 67-year-old woman who had previously undergone a kidney and pancreas transplant and presented with American Joint Committee on Cancer (AJCC) stage IIIA melanoma with subsequent rapid demise. As medicine advances with greater numbers of organ transplant recipients, a multi-institutional prospective study for this at-risk population would be greatly beneficial to help characterize the incidence, progression, and prognosis of melanoma in posttransplant immunosuppressed populations.
恶性黑色素瘤（MM）在免疫功能正常人群中的临床病程和转归已得到充分证实；然而，在免疫抑制人群中却缺乏充分的记录。具体而言，免疫抑制的影响可能导致预后较差，尤其是在黑色素瘤更晚期的病例中。我们报告了一名67岁的女性，她此前接受了肾脏和胰腺移植，被诊断为美国癌症联合委员会（AJCC）III A期黑色素瘤，随后迅速死亡。随着医学的发展，器官移植受者的数量不断增加，针对这一高危人群进行多机构前瞻性研究将非常有助于了解移植后免疫抑制人群中黑色素瘤的发病率、进展情况和预后。
